CL2018001345A1 - Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. - Google Patents

Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.

Info

Publication number
CL2018001345A1
CL2018001345A1 CL2018001345A CL2018001345A CL2018001345A1 CL 2018001345 A1 CL2018001345 A1 CL 2018001345A1 CL 2018001345 A CL2018001345 A CL 2018001345A CL 2018001345 A CL2018001345 A CL 2018001345A CL 2018001345 A1 CL2018001345 A1 CL 2018001345A1
Authority
CL
Chile
Prior art keywords
methyl
disease
trihydroxytetrahydro
cyanoacetyl
methylpiperidin
Prior art date
Application number
CL2018001345A
Other languages
English (en)
Spanish (es)
Inventor
Ryan Hudson
Daniel D Long
Donna A A Wilton
Mandy Loo
Patrick J Brassil
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2018001345A1 publication Critical patent/CL2018001345A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165Heterorings having nitrogen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2018001345A 2015-11-24 2018-05-18 Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. CL2018001345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
CL2018001345A1 true CL2018001345A1 (es) 2018-06-22

Family

ID=57518004

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001345A CL2018001345A1 (es) 2015-11-24 2018-05-18 Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.

Country Status (33)

Country Link
US (3) US10435428B2 (enExample)
EP (1) EP3380486B1 (enExample)
JP (2) JP6778747B2 (enExample)
KR (1) KR20180080330A (enExample)
CN (1) CN108290918B (enExample)
AU (1) AU2016359494B2 (enExample)
BR (1) BR112018010650A8 (enExample)
CA (1) CA3003283A1 (enExample)
CL (1) CL2018001345A1 (enExample)
CO (1) CO2018005327A2 (enExample)
CY (1) CY1122918T1 (enExample)
DK (1) DK3380486T3 (enExample)
EA (1) EA035816B1 (enExample)
ES (1) ES2784523T3 (enExample)
HR (1) HRP20200561T1 (enExample)
HU (1) HUE049775T2 (enExample)
IL (1) IL259076B (enExample)
LT (1) LT3380486T (enExample)
ME (1) ME03757B (enExample)
MX (1) MX383107B (enExample)
MY (1) MY189979A (enExample)
NZ (1) NZ742574A (enExample)
PH (1) PH12018501037A1 (enExample)
PL (1) PL3380486T3 (enExample)
PT (1) PT3380486T (enExample)
RS (1) RS60237B1 (enExample)
SG (1) SG11201803686UA (enExample)
SI (1) SI3380486T1 (enExample)
SM (1) SMT202000242T1 (enExample)
TW (1) TWI703147B (enExample)
UA (1) UA121270C2 (enExample)
WO (1) WO2017091544A1 (enExample)
ZA (1) ZA201802967B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EA035816B1 (ru) 2015-11-24 2020-08-14 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
US10472366B2 (en) 2017-03-08 2019-11-12 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
JP2020520955A (ja) 2017-05-23 2020-07-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ヤヌスキナーゼ阻害剤のグルクロニドプロドラッグ
WO2018217699A1 (en) * 2017-05-23 2018-11-29 Theravance Biopharma R&D Ip, Llc Thiocarbamate prodrugs of tofacitinib
SG11201910198UA (en) * 2017-06-05 2019-11-28 Flagship Pioneering Innovations V Inc Multibiotic agents and methods of using the same
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
WO2019182322A1 (ko) * 2018-03-20 2019-09-26 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
CN119751336A (zh) * 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
CA3119294A1 (en) * 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of inflammatory bowel disease
CN113692278A (zh) 2018-12-19 2021-11-23 因赛特公司 用于治疗胃肠道疾病的jak1途径抑制剂
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CR20220057A (es) 2019-07-10 2022-07-19 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
CR20220058A (es) 2019-07-10 2022-07-19 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230107927A1 (en) * 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4149462A4 (en) 2020-05-14 2024-04-24 Theravance Biopharma R&D IP, LLC Administration of gut-selective jak3 inhibitor
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
WO2022087313A1 (en) * 2020-10-22 2022-04-28 Progenity, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
EP4351584A4 (en) * 2021-06-07 2025-04-23 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE
IL309840A (en) * 2021-07-20 2024-02-01 Coval Biopharma Shanghai Co Ltd An external antidialectic coupling compound drug, and a method of preparation therefor and use thereof
JP2025516712A (ja) * 2022-05-14 2025-05-30 株式会社スリー・ディー・マトリックス 消化管への治療剤の経口投与のための新規な製剤
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
KR20250107797A (ko) 2022-08-17 2025-07-14 트랜센드 테라퓨틱스 인코퍼레이티드 페네틸아민 및 카티논 전구체

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
AU777911B2 (en) 1999-12-10 2004-11-04 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2515913A2 (en) 2009-12-23 2012-10-31 Glycomyr Inc. Use of vitamin d glycosides and sulfates for treatment of disease
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
CN102822177A (zh) * 2010-02-05 2012-12-12 美国辉瑞有限公司 吡咯并[2,3-d]嘧啶脲化合物
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
CA2913752A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP3169348B1 (en) * 2014-06-24 2019-07-31 Institut National de la Sante et de la Recherche Medicale (INSERM) Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases
EA035816B1 (ru) 2015-11-24 2020-08-14 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пролекарства jak-ингибирующего соединения для лечения воспалительного заболевания желудочно-кишечного тракта
WO2017106957A1 (en) 2015-12-23 2017-06-29 The University Of British Columbia Lipid-linked prodrugs
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
EP3380486B1 (en) 2020-02-19
JP6778747B2 (ja) 2020-11-04
NZ742574A (en) 2018-11-30
SI3380486T1 (sl) 2020-07-31
JP2020196742A (ja) 2020-12-10
PT3380486T (pt) 2020-05-22
LT3380486T (lt) 2020-05-11
KR20180080330A (ko) 2018-07-11
SMT202000242T1 (it) 2020-07-08
ME03757B (me) 2021-04-20
MY189979A (en) 2022-03-22
HRP20200561T1 (hr) 2020-06-26
JP2019501133A (ja) 2019-01-17
ZA201802967B (en) 2019-04-24
TWI703147B (zh) 2020-09-01
AU2016359494B2 (en) 2021-01-07
HUE049775T2 (hu) 2020-10-28
US11608354B2 (en) 2023-03-21
WO2017091544A1 (en) 2017-06-01
CA3003283A1 (en) 2017-06-01
CN108290918A (zh) 2018-07-17
CY1122918T1 (el) 2021-10-29
US10435428B2 (en) 2019-10-08
UA121270C2 (uk) 2020-04-27
TW201720827A (zh) 2017-06-16
RS60237B1 (sr) 2020-06-30
IL259076A (en) 2018-06-28
IL259076B (en) 2021-05-31
PL3380486T3 (pl) 2020-07-27
US20210179655A1 (en) 2021-06-17
US20190389895A1 (en) 2019-12-26
MX2018006282A (es) 2019-01-21
US20170145044A1 (en) 2017-05-25
EA035816B1 (ru) 2020-08-14
EP3380486A1 (en) 2018-10-03
US10961267B2 (en) 2021-03-30
ES2784523T3 (es) 2020-09-28
EA201891248A1 (ru) 2018-10-31
CN108290918B (zh) 2021-06-08
BR112018010650A8 (pt) 2019-02-26
BR112018010650A2 (pt) 2018-11-13
MX383107B (es) 2025-03-13
CO2018005327A2 (es) 2018-05-31
AU2016359494A1 (en) 2018-06-14
SG11201803686UA (en) 2018-06-28
PH12018501037A1 (en) 2019-01-28
DK3380486T3 (da) 2020-05-18

Similar Documents

Publication Publication Date Title
CL2018001345A1 (es) Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.
WO2015132799A3 (en) Heterocyclic compounds
HK1255102A1 (zh) 杂环化合物及其应用
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
IN2014KN00948A (enExample)
MY197116A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
EA201600622A1 (ru) Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
EP3393647A4 (en) PROCESS FOR CAPACITING SOLUBLE BIOLOGICS, THERAPEUTICS AND CONTRASTANTS
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
MY193728A (en) Muscarinic receptor agonists
PH12018500653B1 (en) Salts and solid forms of monobactam antibiotic
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
IT1399223B1 (it) Apparato per lavorare cornici di infissi.
EA201790570A1 (ru) Модуляторы р2х7
WO2013109972A3 (en) Therapeutic compounds
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
IL261196A (en) A pharmaceutical preparation for cancer, containing a polyphenol compound as an active ingredient
EP3103453A4 (en) Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
EA201691741A1 (ru) Фармацевтическая композиция
WO2015001541A3 (en) Pharmaceutical film composition
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
EP3313835A4 (en) PROCESS FOR THE PREPARATION OF OLTIPRAZ
EP3383956A4 (en) IMPROVED METHOD FOR THE MANUFACTURE OF INDIGO CARMINE